Frozen tissues samples are tissues from the human body that are used for research for disease diagnosis, treatment, cancers, and morphological analysis. Frozen tissue samples can be of three types – frozen normal tissues, frozen diseased tissues, and frozen tumor tissues. Frozen tissue samples are preferred in analyses such as next-generation sequencing, western blotting for post-translational protein modifications, mass spectrometry, and quantitative real-time polymerase chain reaction. The biopsy material is dipped in liquid nitrogen and stored in an ultra-cold freezer. Frozen tissue samples are the gold standard for DNA and RNA sequencing, especially when the strands must be longer than 50 pairs. In immunohistochemistry, frozen tissue samples are also helpful as the proteins are still preserved in their native state. The market players in the frozen tissues samples market collect and create biorepositories of these frozen tissues samples and provide them to clients in the form of frozen tissue samples, frozen tissue arrays, and frozen tissue panels, as per client requirements. These biorepositories have increased significantly, with government and research organizations also creating their own biobanks for the collection and storage of tissue samples. Various market players also provide custom services to collect fresh tissues for specific diseases as per client requirements.
OriGene Technologies And Audubon Bioscience – Notable Market Players in Frozen Tissues Samples Market
Leading companies operating in the market have undertaken various organic and inorganic growth strategies in the frozen tissues samples market. The primary market players in the frozen tissues samples market include ProteoGenex, Inc.; BioChain Institute, Inc.; OriGene Technologies, Inc.; ZenBio, Inc.; Geneticist, Inc.; AMS Biotechnology (Europe) Ltd.; US Biolab Corp., Inc.; Bay Biosciences LLC; REPROCELL, Inc.; and Audubon Bioscience Co., among others. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the market players have also deployed several inorganic strategies, including mergers & acquisitions, partnerships, and collaborations.
Below are the major growth strategies undertaken by the players operating in the global frozen tissues samples market:
| Year | News |
| Dec-2021 | AMS Biotechnology (Europe) Ltd. opened a new office in Alkmaar, Netherlands. By maintaining local stock – AMSBIO Europe BV enables EU customers to order and receive the company’s market-leading life science products with unimpeded efficiency and lower costs in the post-Brexit market. |
| Nov-2021 | Audubon partnered with MicroVentures, an equity crowdfunding platform, to carry out a campaign to help finance the company’s global expansion. The company raised US$ 348,456 from 763 investors. |
| Oct-2021 | REPROCELL and Hoth Therapeutics, Inc. extended their partnership agreement to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). In the partnership, fresh explants of ulcerative colitis and Crohn’s disease tissues will be used to investigate the therapeutic potential of Hoth’s HT-003 drugs. Also, all testing will be performed at REPROCELL’s Centre for Predictive Drug Discovery. |
| May-2019 | VIROCLINICS-DDL announced the signing of renewal for the collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects. As per the collaboration, REPROCELL provided sample processing services in Japan to VIROCLINICS-DDL and supported COVID-19 clinical research projects from May 2021 until July 2021. REPROCELL joined VIROCLINICS-DDL’s extensive global processing laboratory network to assist with several clinical research studies. |
